Andrew Combs was educated at the University of Wisconsin-Madison where he received B.S. degrees in Chemistry and Molecular Biology (1984-1988). He received his Ph.D. in Organic Chemistry at UCLA (1994) and then joined Professor Stuart L. Schreiber's laboratory at Harvard University as a Post-Doctoral Fellow (1994-1996). Andrew joined DuPont-Merck Pharmaceuticals Company in 1996 where he initiated and led a target-directed combinatorial chemistry team. In 2000, Andrew was promoted to Director at DuPont Pharmaceuticals where he also led several medicinal chemistry teams, including projects in CNS and oncology. In 2003, Andrew joined Incyte as a Senior Director in Discovery Chemistry where he currently oversees a medicinal chemistry team targeting phosphatases, the targeted synthesis technologies group and the analytical technologies group for the department. Andrew's research interests focus on the application of combinatorial, parallel and microwave-assisted synthesis technologies to drug discovery. He has published numerous papers and patents. He is also currently an editorial advisor for J. Comb. Chem., J. Molecular Diversity, and QSAR & Combinatorial Sciences.

Frank Fang is currently Senior Executive Director at Eisai Research Institute, and joined the CMLD-BU SAB in 2006.

Sam Gerritz received his bachelor's degree in chemistry in 1988 from the College of Wooster, where he conducted senior research with Professor Paul Gaus. He was an NSF Predoctoral Fellow at Massachusetts Institute of Technology and joined the group of the late Satoru Masamune. At M.I.T., Sam's research focused on the total synthesis of Calyculin A. In 1993, Sam received his Ph.D. from M.I.T. and joined Glaxo in Research Triangle Park, North Carolina. During his tenure at Glaxo, Sam’s research focused on the application of combinatorial chemistry to ongoing drug discovery projects. In 2001, Sam moved to Bristol-Myers Squibb in Wallingford, Connecticut, as a Group Leader in the Lead Synthesis group. Sam serves on the editorial boards of the Journal of Combinatorial Chemistry and Current Topics in Medicinal Chemistry and is an adjunct professor at Quinnipiac University.

Jack Hodges completed his Bachelors degree in Chemistry at the University of Delaware and Doctorate in Medicinal Chemistry at the University of Arizona. After a two-year postdoctoral fellowship at the University of Rochester, he joined the pharmaceutical discovery effort at Parke-Davis in Ann Arbor, MI. He accumulated 21 years of experience as a drug discovery chemist before taking a position as Vice President of Chemistry at Berry & Associates, Inc., in Dexter, MI. Jack has been closely associated with the field of combinatorial chemistry, publishing numerous papers, including seminal articles on the topic of polymer-supported scavengers.

Dr. Miller received his B.A.(1989), M.A.(1989) and Ph.D.(1994) from Harvard University, and worked under Professor David Evans as a National Science Foundation Predoctoral Fellow. He later joined the California Institute of Technology as a National Science Foundation Postdoctoral Fellow under Professor Robert Grubbs. From 1996 to 2006, Dr. Miller served as a Professor of Chemistry at Boston College before joining the Chemistry Department at Yale University as a Professor of Organic Chemistry. Dr. Miller's research program focuses on problems in asymmetric catalysis and synthesis. His efforts employ strategies that include catalyst design, the development of combinatorial techniques for catalyst screening, and the application of these approaches to complex molecule synthesis. Specific areas of interest include enantioselective acyl transfers, conjugate additions, phosphorylations, sulfations and carbon-carbon bond forming reactions.

Dr. Roth is currently a Professor in the Department of Pharmacology at the University of North Carolina School of Medicine and the Director of the Mental Health Psychoactive Drug Screening Program (NIMH-PDSP). Dr. Roth received his M.D./ Ph.D. in Biochemistry from St. Louis University Medical School and completed post-doctoral training in the Laboratory of Preclinical Pharmacology at the NIMH under the supervision of 'Mimo' Costa. Dr. Roth's research is devoted to discovering how psychoactive compounds exert their actions at levels ranging from the most fundamental (e.g. atomic) to the most applied (e.g. human). Over the past two decades, Dr. Roth has contributed nearly 200 publications and has made major contributions to our understanding of GPCR structure and function, particularly related to CNS drug discovery.

Greg Roth studied under the direction of Professor A. I. Meyers and received a Ph.D. in Chemistry from Colorado State University in 1988. Over the past 15 years has contributed to process, combinatorial and medicinal chemistry research programs at Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, and Abbott Laboratories Bioresearch Center in Worcester, MA. He is presently an Associate Professor and Director of Medicinal Chemistry and Pharmacology at the Burnham Institute for Medical Research at Lake Nona, Florida.